BELITE BIO (BLTE) director Longo reports 110,000-share stock option holdings

Rhea-AI Filing Summary

BELITE BIO director John Michael Longo reported his initial beneficial ownership on a Form 3, showing two stock option awards over ordinary shares. One option allows him to buy 50,000 shares at $6.0000 per share, expiring on April 17, 2032, vesting monthly from April 28, 2022 over three years. A second option covers 60,000 shares at an exercise price of $58.8800, expiring on April 14, 2035, vesting in 36 equal monthly installments starting after April 15, 2025, subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Longo John Michael

(Last) (First) (Middle)

3 BUTTONWOOD COURT

(Street)

MONROE TOWNSHIP NEW JERSEY 08831

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	04/17/2032	Ordinary Shares	50,000	$6	D
Stock Option (right to buy)	(2)	04/14/2035	Ordinary Shares	60,000	$58.88	D

Explanation of Responses:

1. The option shall vest (i) as to 20,000 ordinary shares subject to the option in 12 equal and continuous monthly installments for each full month of services completed following April 28, 2022, and (ii) as to the remaining 30,000 ordinary shares subject to the option in 24 equal and continuous monthly installments for each full month of services completed following the first anniversary of April 28, 2022, subject to continued service to the Issuer on each such date.

2. The option shall vest as to 60,000 ordinary shares subject to the option in 36 equal and continue monthly installments for each full month of services completed following April 15, 2025, subject to continued service to the Issuer on such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ John Michael Longo	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BELITE BIO (BLTE) Form 3 filing by John Michael Longo report?

The Form 3 filing reports director John Michael Longo’s initial beneficial ownership in BELITE BIO through two stock option grants. It lists the option exercise prices, expiration dates, and vesting schedules tied to his continued service with the company.

How many BELITE BIO (BLTE) shares are covered by John Michael Longo’s stock options?

The filing shows stock options over a total of 110,000 ordinary shares. One option covers 50,000 shares and another covers 60,000 shares, each with its own exercise price, expiration date, and service-based vesting schedule.

What are the exercise prices of John Michael Longo’s BELITE BIO (BLTE) options?

The Form 3 discloses two exercise prices: one option is exercisable at $6.0000 per ordinary share, and the other at $58.8800 per ordinary share. These prices apply if Longo exercises the options before their respective expiration dates.

How do John Michael Longo’s BELITE BIO (BLTE) options vest over time?

The 50,000-share option vests in monthly installments over three years starting from April 28, 2022. The 60,000-share option vests in 36 equal monthly installments after April 15, 2025, with vesting conditioned on his continued service to BELITE BIO.

When do John Michael Longo’s BELITE BIO (BLTE) stock options expire?

The option for 50,000 ordinary shares expires on April 17, 2032, while the option for 60,000 ordinary shares expires on April 14, 2035. After these expiration dates, any unexercised option portions cannot be used.

Does the BELITE BIO (BLTE) Form 3 show any stock purchases or sales by John Michael Longo?

The Form 3 does not report any stock purchases or sales. It only lists existing stock option holdings, including underlying ordinary share amounts, exercise prices, expiration dates, and service-based vesting terms for each option grant.